Urol. praxi, 2012; 13(6): 239-244

Herbal drugs for the treatment of symptoms of benign prostatic hyperplasia

prof.MUDr.RNDr.Luboslav Stárka, DrSc.1, PharmDr.Lucie Sosvorová1,2, Mgr.Petra Mikšátková2
1 Endokrinologický ústav, Praha
2 Vysoká škola chemicko-technologická, Praha

A revival of interest in phytotherapeutic agents for the treatment of benign prostate hyperplasia and prostate carcinoma, both in Europe

and North America, can be ascribed to an intensive propagation and to an easy access to these drugs and especially to a the patients’ dissatisfaction

with the adverse effects of the medical alternatives. There exists a handful of herbal drugs with various types of mechnisms

of action. One of the most frequently prescribed and studied such agents is Serenoa repens extract. Those, which are available on the

inland market are breifly characterised here.

Keywords: benign prostatic hyperplazia, lower urinary tract symptoms, phytotherapy, herbal drugs

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stárka L, Sosvorová L, Mikšátková P. Herbal drugs for the treatment of symptoms of benign prostatic hyperplasia. Urol. praxi. 2012;13(6):239-244.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chan JM, Elkin EP, Silva SJ, Broering JM, Latini DM, Carroll PR. Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer. Urology. 2005; 66(6): 1223-1228. Go to original source... Go to PubMed...
    2. Boon H, Westlake K, Stewart M, et al. Use of complementary/alternative medicine by men diagnosed with prostate cancer: Prevalence and characteristics. Urology. 2003; 62: 849-853. Go to original source... Go to PubMed...
    3. Juliao AA, Plata M, Kazzazi A, Bostanci Y, Djavan B. American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited. Curr Opin Urol. 2012; 22(1): 34-39. Go to original source... Go to PubMed...
    4. Wilt TJ, Macdonald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2011; (5): CD001042. Go to original source...
    5. Wilt T, Ishani A, Mac Donald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002; (1): CD001044. Go to original source...
    6. Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009; (2): CD001423. Go to original source...
    7. Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006; 354(6): 557-566. Go to original source... Go to PubMed...
    8. Lowe FC, Ku JC. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology. 1996; 48(1): 12-20. Go to original source... Go to PubMed...
    9. Wilt TJ, Ishani A, Rutks I, MacDonald R. Phytotherapy for benign prostatic hyperplasia. Public Health Nutr. 2000; 3(4A): 459-472. Go to original source... Go to PubMed...
    10. Hizli F, Uygur MC. A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. Int Urol Nephrol. 2007; 39(3): 879-886. Go to original source... Go to PubMed...
    11. Rösler TW, Matusch R, Weber B, Schwarze B. Analysis of the hydrodistillate from the fruits of Serenoa repens. Planta Med. 2009; 75: 184-186. Go to original source... Go to PubMed...
    12. Buck AC. Is there a scientific basis for the therapeutic effects of Serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol. 2004; 172: 1792-1799. Go to original source... Go to PubMed...
    13. Geavlete P, Multescu R, Geavlete B. Serenoa repens extract in the treatment of benign prostatic hyperplasia. Ther Adv Urol. 2011; 3(4): 193-198. Go to original source... Go to PubMed...
    14. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. Guidelines on the treatment of non-neurogenic male LUTS. EAU online Guidelines. 2011, viz: http://www.uroweb.org/gls/pdf/12_Male_LUTS.pdf.
    15. Sinescu I, Geavlete P, Multescu R, Gangu C, Miclea F, Coman I, Ioiart I, Ambert V, Constantin T, Petrut B, Feciche B. Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. Urol Int. 2011; 86(3): 284-289. Go to original source... Go to PubMed...
    16. Agbabiaka TB, Pittler MH, Wider B, Ernst E. Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf. 2009; 32(8): 637-647. Go to original source... Go to PubMed...
    17. Schleich S, Papaioannou M, Baniahmad A, Matusch R. Extracts from Pygeum africanum and other ethnobotanical species with antiandrogenic activity. Planta Med. 2006; 72(9): 807-813. Go to original source... Go to PubMed...
    18. Papaioannou M, Schleich S, Roell D, Schubert U, Tanner T, Claessens F, Matusch R, Baniahmad A. NBBS isolated from Pygeum africanum bark exhibits androgen antagonistic activity, inhibits AR nuclear translocation and prostate cancer cell growth. Invest New Drugs. 2010; 28(6): 729-743. Go to original source... Go to PubMed...
    19. Roell D, Baniahmad A. The natural compounds atraric acid and N-butylbenzene-sulfonamide as antagonists of the human androgen receptor and inhibitors of prostate cancer cell growth. Mol Cell Endocrinol. 2011; 332(1-2): 1-8. Go to original source... Go to PubMed...
    20. Quiles MT, Arbós MA, Fraga A, de Torres IM, Reventós J, Morote J. Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH). Prostate. 2010; 70(10): 1044-1453. Go to original source... Go to PubMed...
    21. Shenouda NS, Sakla MS, Newton LG, Besch-Williford C, Greenberg NM, MacDonald RS, Lubahn DB. Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo. Endocrine. 2007; 31(1): 72-81. Go to original source... Go to PubMed...
    22. Edgar AD, Levin R, Constantinou CE, Denis L. A critical review of the pharmacology of the plant extract of Pygeum africanum in the treatment of LUTS. Neurourol Urodyn. 2007; 26(4): 458-463. Go to original source... Go to PubMed...
    23. Steenkamp V, Gouws MC, Gulumian M, Elgorashi EE, van Staden J. Studies on antibacterial, anti-inflammatory and antioxidant activity of herbal remedies used in the treatment of benign prostatic hyperplasia and prostatitis. J Ethnopharmacol. 2006; 103(1): 71-75. Go to original source... Go to PubMed...
    24. Hevesi Tóth B, Blazics B, Kéry A. Polyphenol composition and antioxidant capacity of Epilobium species. J Pharm Biomed Anal. 2009; 49(1): 26-31. Go to original source... Go to PubMed...
    25. Hevesi BT, Houghton PJ, Habtemariam S, Kéry A. Antioxidant and antiinflammatory effect of Epilobium parviflorum Schreb. Phytother Res. 2009; 23(5): 719-724. Go to original source... Go to PubMed...
    26. Kiss AK, Bazylko A, Filipek A, Granica S, Jaszewska E, Kiarszys U, Kośmider A, Piwowarski J. Oenothein B's contribution to the anti-inflammatory and antioxidant activity of Epilobium sp. Phytomedicine. 2011; 18(7): 557-560. Go to original source... Go to PubMed...
    27. Lesuisse D, Berjonneau J, Ciot C, Devaux P, Doucet B, Gourvest JF, Khemis B, Lang C, Legrand R, Lowinski M, Maquin P, Parent A, Schoot B, Teutsch G. Determination of oenothein B as the active 5-alpha-reductase-inhibiting principle of the folk medicine Epilobium parviflorum. J Nat Prod. 1996; 59(5): 490-492. Go to original source... Go to PubMed...
    28. Gossell-Williams M, Davis A, O'Connor N. Inhibition of testosterone-induced hyperplasia of the prostate of sprague-dawley rats by pumpkin seed oil. J Med Food. 2006; 9(2): 284-286. Go to original source... Go to PubMed...
    29. Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother. 2005; 5(4): 1-11. Go to original source...
    30. Bercovich E, Saccomanni M. Analysis of the results obtained with a new phytotherapeutic association for LUTS versus control. Urologia. 2010; 77(3): 180-186. Go to original source... Go to PubMed...
    31. Lopatkin N, Sivkov A, Schläfke S, Funk P, Medvedev A, Engelmann U. Efficacy and safety of a combination of Sabal and Urtica extract in lower urinary tract symptoms-long-term follow-up of a placebo-controlled, double-blind, multicenter trial. Int Urol Nephrol. 2007; 39(4): 1137-1146. Go to original source... Go to PubMed...
    32. Nahata A, Dixit VK. Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia. 2011. doi: 10.1111/j.1439-0272.2011.01197.x. Go to original source... Go to PubMed...
    33. Hirano T, Homma M, Oka K. Effects of stinging nettle root extracts and their steroidal components on the Na+, K(+) -ATPase of the benign prostatic hyperplasia. Planta Med. 1994; 60(1): 30-33. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.